On-line version ISSN 1518-8787
Rev. Saúde Pública vol.36 n.2 São Paulo Apr. 2002
Exantema após vacinação do sarampo: análise laboratorial de casos notificados em São Paulo
Maria I Oliveiraa, Suely P Curtia, Cristina A Figueiredoa, Ana MS Afonsoa, Márcia Theobaldoa, Raymundo S Azevedob and Edison L Durigonc
aServiço de Virologia do Instituto Adolfo Lutz. São Paulo, SP, Brasil. bDepartamento de Patologia da Faculdade de Medicina da Universidade de São Paulo. São Paulo, SP, Brasil. cInstituto de Ciências Biomédicas da Universidade de São Paulo. São Paulo, SP, Brasil
| DESCRITORES |
Vacinação do sarampo. Parvovírus humano B19. Herpes vírus humano 6. Exantema. Rubéola. Sarampo.
The scarcity of clinical disease, as an expected outcome of an effective measles vaccination program, makes it more difficult for clinicians to diagnose correctly the etiology of exanthematic diseases. Also, atypical cases may occur due to other viruses and be mistaken as measles. Studies on immune responses after measles vaccination showed clinical reactions, such as fever and rash, observed 10 days after immunization. This has led to the hypothesis that an abnormally intense cellular immune response may account for vaccine-induced measles infection.13 The classic measles is typically a childhood infection with high fever for 2 to 3 days, and a rash that coincides with the appearance of the immune response.6,7 But many childhood viral diseases may present rash and fever, namely: rubella, human herpes 6 (HHV 6) and human parvovirus B19 (HPV B19), among others.
HHV 6 was recognized as the agent responsible for exanthema subitum/roseola, which occurs at an early age, between the ages of 6 and 18 months. It is the most common infectious exanthema during the first two years of life; 82% of all cases occur during this period, and it is characterized by a febrile episode that lasts 3 to 5 days, skin rashes developing after fever, and the rashes continuing to affect pigmentation. This leads to antibody prevalence of up to 80-100% in adults. Although low prevalence was found in some areas, further comparisons are necessary to determine the differences between various racial and ethnic groups and the geographic distribution of the virus.15
HPVB19 infection can occur in all age groups. The reported seroprevalence ranges from 15% to 60% in children aged 5-19 years. The level of transmission in a community seems to vary from year to year. A facial rash is characteristic of the illness, but it also occurs on the torso and extremities. Recurrence of the rash may take place several weeks following nonspecific stimuli such as change in temperature.2
The disease caused by the rubella virus is more important when the infection occurs in pregnant women during the first trimester, causing defects in organ formation of the fetus. Rubella virus can be congenitally acquired. It can be recovered from nasopharyngeal secretions of 50-60% infants by the age of 3 months and from about 10% by the age of 9-12 months.
Typical rubelliform rashes may be a result of enterovirus, HPVB19, and some arboviruses infections, which may cause both rubelliform rashes and arthralgia. Rubella vaccines are well tolerated, although rash, lymphadenopathy and arthropathy may occur between 10 days to 4 weeks after vaccination.3
Differential diagnosis among measles virus (MV), rubella virus (RV), HPV B19 and HHV 6 infections has been associated with a variety of other exanthemas, particularly if the patient shows a rash after the classic prodromic phase, which increases the difficulty of an accurate diagnosis based on clinical symptoms.7
The present study aims to establish the etiology of rash after measles vaccination by laboratory analysis of sera taken from cases reported in the state of São Paulo, Brazil.
Patients and samples
There were 109 cases of measles confirmed in 1999, reported to the Health Department of the state of São Paulo as part of the Measles Surveillance Program. Seventeen cases of children with manifested symptoms after measles immunization were studied. The vaccinated children aged 9 to 12 months and presented exanthema 1 to 60 days after measles vaccination with clinical hypotheses of measles or rubella infection (Table).
Blood samples were collected and their sera were tested for IgM specific following the manufacturer instructions. Polimerase chain reaction (PCR) was used to detected measles virus (MV), rubella virus (RV), HHV 6 and HPV B19.
Measles virus (MV)
Measles virus specific IgM were tested with three different kits:
1) Measles IgM capture enzyme immunoassay ¾ CDC, Atlanta, GA;
2) Measles IgM capture enzyme immunoassay;
3) Enzygnost® anti-masern ¾ virus/IgM.
The detection of MV RNA was from serum RNA isolated using protocols of RNA isolation for acid guanidinium isothiocyanate-phenol-chloroform extraction and reverse transcriptase (RT-PCR). The methods and primers were described by Rota.11
Rubella virus (RV)
The assay used for the detection of RV antibodies was the Rubenostika IgM II micro Elisa system.
The detection of RV in sera was done from total RNA extracted using the guanidinium isothiocyanate method and reverse transcriptase-PCR (RT-PCR) followed by Nested-PCR. The methods and primers were described by Jennifer.3
Human herpes virus 6 (HHV 6)
HHV 6 IgM immunofluorescence assay was used.
The detection of HHV 6 in the sera was done using phenol and chloroform treatment and alcohol precipitation. The Nested-PCR assay with primers and methods were described by Huang.15
Human parvovirus B19 (HPV B19)
HPV B19 sera samples were tested using ELISA to detect IgM antibodies specific to parvovirus B19.
The detection of HPVB19 DNA in sera was done by using the method of detergent and proteinase K for DNA extraction. Oligonucleotides for Nested-PCR assay were described by Durigon.5
The following results were obtained from 17 children aged 9 and 12 months with exanthema after measles immunization.
In 17 sera were tested to detect specific IgM antibody and viremia for each virus using PCR assay. The results were positive for measles virus, and negative for rubella virus. The time of vaccination and blood collection was between 6 to 60 days.
In addition, 17.6% (3 in 17) were positive for HPV B19, and 76.5% (13 in 17) tested positive for HHV 6. The time of rash onset and blood collection was between 0 to 13 days.
Therefore, the possibility of rash due to measles vaccine could be suspected only in one child (5.9%), given that his/her serum tested negative for three virus infections: HHV 6, RV, and HPV B19. The time between vaccination and blood collection was 15 days, and the time between vaccination and rash onset rash was 1 day. In 3 children positive for HPV B19, the infection occurred in the months of July, August, and September. HHV 6 infections occurred throughout the year.
The final diagnosis for each child is shown in Table.
A clinical diagnosis of rash causing infections is not always possible and reliance has to be placed on serological evidence of infection, especially in the presence of specific immunoglobulin IgM. In patients presenting a history of rash the least to consider is the hypothesis of measles, rubella, HPVB19, and HHV 6 infection. Vaccine induced exanthema has also to be considered.12
The immune responses to MV are important for the virus clearance and recovery from infection, and are directly responsible for several clinical manifestations of measles.6
A previous study on individuals who developed detectable measles IgM after natural measles infections demonstrated that 77% developed IgM 4 to 11 days after the onset of the rash. Moreover, more than 90% of the individuals remained IgM positive for 28 days. The interpretation of positive IgM results from individuals with suspected natural measles infections becomes more difficult if these individuals have been recently vaccinated. The timing of the rise and decline of measles IgM in the first 4 to 8 weeks after primary vaccination has not been well documented.1,8 In the present study this time was 6 to 29 days after vaccination. MV was positive in all samples. In 4 samples this time was 60 days and more studies with other samples should be performed.8
The recommended age of immunization has varied from 6 to 15 months of age and remains a subject of discussion. Children between 9 to 12 months of age were studied, wherein the probability of seroconversion is determined by the level of persisting MV-specific maternal antibodies in the infant. In addition, some investigators have reported decreased rates of seroconversion in children.1
HHV 6 is uncommon in infants younger than 6 months of age. This is suggestive of the protective effect of maternal antibodies. The disease shows a distinct seasonal variation: most cases occur during springtime.15 Cases of virus circulating were seen all year round. Of all cases, 76.5% were HHV 6, confirming the clinical manifestation seen in 82% during the first 24 months of life.15 For HPV B19, it was 17.6%.
HPVB19 occurs most commonly in the 5-to-14-year-old age group during winter and springtime. The 3 children with confirmed HPV B19 infection showed symptoms during this period.2
For HPVB19 the viremia occurs approximately one week after inoculation and lasts for 3 to 5 days. There is no evidence of persistent viremia at the time of the rash, which occurs 4 to 8 days later.2,4 HPV B19 IgM and viremia using PCR were detected when the time between the rash onset and blood collection was 0 to 3 days.
The incubation of HHV6 infantum is 7 to 15 days. The disease does not have a prodromic phase. The onset is heralded by high fever, at least 38.8°C and often as high as 40.5°C. The fever typically lasts 3 days and may be intermittent. It is accompanied by a characteristic rash.15 The blood-collection time was between 0 to 13 days after the rash onset and during this time IgM and viremia were detected using PCR.
Only one serum in 17 was reactive to measles virus (specific IgM and RT-PCR) and the time between vaccination and the rash onset was 16 days. A possible alternative to reach a definitive diagnosis would be to sequence MV to verify if it was a wild measles infection or a measles vaccine virus.14 Another possibility is that the rash is due to a second infection not tested.
The study results confirm that there is a simultaneous IgM reactivity against more than one virus in measles, HPVB19 and HHV 6 infections. In recent vaccination 3 in 17 sera were also reactive to HPVB19 specific, and 13 in 17 sera were also reactive to HHV 6.
Early in the 1980s reports showed cases of simultaneous appearance of specific IgM against rubella virus and HPVB19.3,5 In 1997, Jensen9 demonstrated the simultaneous existence of IgM against measles and rubella with antibodies against other viruses such as Epstein Barr virus (EBV), cytomegalovirus (CMV), and HPV B19.
The study results indicate to the need to include in the differential diagnosis HHV 6 and HPV B19, both infections with rash as a clinical manifestation. The simultaneous occurrence of these two infections is important for epidemiological surveillance, mainly because etiological misdiagnosis of rash can put into question the safety of measles vaccine and decrease the public adherence to immunization programs.
The team of the Division of Transmissible Respiratory Diseases of the Centro de Vigilância Epidemiologica da Secretaria da Saúde do Estado de São Paulo (Epidemiological Surveillance Center of the Health Department of the state of São Paulo) for the contribution of the clinical history of the patients.
1. Advances in global measles control and elimination. MMWR Mob Mortal Wkly Rep 1998;(47):16-7. [ Links ]
2. Anderson LJ, Young NS, editors. Human parvovirus B19. New York: Karger; 1997. (Monographs in Virology, 20). [ Links ]
3. Best JM. Rubella virus. In: Lennette EH, Schmidit NJ, editors. Diagnostic procedures for viral, rickettsial and chlamydial infections. 7th ed. Washington (DC): American Public Health Associations; 1995. p. 583-600. [ Links ]
4. Cohen BJ, Shirley DU. Dual infection with rubella and human parvovirus. Lancet 1985;2:662-3. [ Links ]
5. Durigon EL, Erdman DD, Gary GW, Pallansch MA, Torok TT, Anderson LJ. Multiple primer pairs for polimerase chain reaction (PCR) amplification of human parvovirus B19 DNA. J Virol Methods 1993;44:155-65. [ Links ]
6. Ferson MJ, Young LC, Robertson PW, Whybin LR. Difficulties in clinical diagnosis of measles, proposal for modified clinical case definition. Med J Aust 1995;163:364-6. [ Links ]
7. Griffin DE, Bellini WJ. Measles virus. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott ¾ Raven; 1996. p. 1267-312. [ Links ]
8. Helfand RF, Kebede S, Gary Jr-HE, Beyene H, Bellini W. Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination. Clin Diagn Lab Immunol 1999;6:178-80. [ Links ]
9. Jensen IP, Vestergaard BF. Assessment of the specificity of a commercial human parvovirus B19 IgM assay. Clin Diagn Virol 1997;7:133-7. [ Links ]
10. Kurtz JB, Anderson MJ. Cross-reactions in rubella and parvovirus B19 specific IgM tests. Lancet 1985;2:1356. [ Links ]
11. Rota PA, Khan AS, Durigon EL, Yuran T, Villamargo YS, Bellini WJ. Detction of measles virus RNA in urine specimens from vaccine recipients. J Clin Microbiol 1995;33:2485-8. [ Links ]
12. Thomas J, Barrett E, Hesketh LM, Wynne A, Morgan-Capner P. Simultaneous IgM reactivity by EIA against more than one virus in measles, parvovirus B19, and rubella infection. J Clin Virol 1999;14:107-18. [ Links ]
13. Vardas E, Kreis S. Isolation of measles virus from a naturally-immune asymptomatically re-infected individual. J Clin Virol 1999;13:173-9. [ Links ]
14. World Health Organization. Standardisation of the nomenclature for describing the genetic characteristics of wild-type measles viruses. Wkly Epidemiol Rec 1998;35:265-9. [ Links ]
15. Yalcin S, Yamanishi K. Human Herpesvirus 6 (HHV-). In: Lennette EH, Schmidit NJ, editors. Diagnostic procedures for viral, rickettsial and chlamydial infections. 7th ed. Washington (DC): American Public Health Associations; 1995. p. 397-405. [ Links ]
Maria I. Oliveira
Instituto Adolfo Lutz
Av. Dr. Arnaldo, 355
01246-902 São Paulo, SP, Brasil
Supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (Fapesp ¾ Processo nº 01/01661-3).
Received on 1/3/2001. Reviewed on 3/10/2001. Approved on 17/12/2001.